Literature DB >> 1373484

Identification of distinct populations of PI-3 kinase activity following T-cell activation.

P A Thompson1, J S Gutkind, K C Robbins, J A Ledbetter, J B Bolen.   

Abstract

Activation of mature CD4+ T lymphocytes by antigen-presenting cells involves engagement of the CD3/T-cell antigen receptor complex along with the CD4 surface glycoprotein and the phosphorylation of cellular proteins on tyrosine residues leading to stimulation of a variety of cellular second-messenger systems. Several recent studies have implicated non-receptor protein tyrosine kinase of the src family, especially p56lck and p59fyn, in mediating at least a portion of these tyrosine phosphorylation events. In the present study we have examined the involvement of one type of second-messenger system, phosphatidylinositol-3 kinase (PI-3 kinase), in signal transduction during antibody-induced activation of normal resting human CD4+ T cells. We demonstrate that PI-3 kinase activity is increased following co-approximation of CD4 with the T-cell receptor and that PI-3 kinase activity co-precipitates with the CD4-p56lck complex. We also show that following T-cell activation a complex containing PI-3 kinase activity can be demonstrated in CD3 epsilon immunoprecipitates which is distinct from that which interacts with p56lck.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373484

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  The SH3 domain of p56lck is involved in binding to phosphatidylinositol 3'-kinase from T lymphocytes.

Authors:  L B Vogel; D J Fujita
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

Review 2.  CD28: a signalling perspective.

Authors:  S G Ward
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

3.  Tyrosine phosphorylation of CD45 phosphotyrosine phosphatase by p50csk kinase creates a binding site for p56lck tyrosine kinase and activates the phosphatase.

Authors:  M Autero; J Saharinen; T Pessa-Morikawa; M Soula-Rothhut; C Oetken; M Gassmann; M Bergman; K Alitalo; P Burn; C G Gahmberg
Journal:  Mol Cell Biol       Date:  1994-02       Impact factor: 4.272

4.  Src-homology 3 domain of protein kinase p59fyn mediates binding to phosphatidylinositol 3-kinase in T cells.

Authors:  K V Prasad; O Janssen; R Kapeller; M Raab; L C Cantley; C E Rudd
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

5.  Wortmannin blocks lipid and protein kinase activities associated with PI 3-kinase and inhibits a subset of responses induced by Fc epsilon R1 cross-linking.

Authors:  S A Barker; K K Caldwell; A Hall; A M Martinez; J R Pfeiffer; J M Oliver; B S Wilson
Journal:  Mol Biol Cell       Date:  1995-09       Impact factor: 4.138

6.  Phosphatidylinositol (PI) 3-kinase and PI 4-kinase binding to the CD4-p56lck complex: the p56lck SH3 domain binds to PI 3-kinase but not PI 4-kinase.

Authors:  K V Prasad; R Kapeller; O Janssen; H Repke; J S Duke-Cohan; L C Cantley; C E Rudd
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

7.  Activation of phosphatidylinositol 3-kinase by concanavalin A through dual signaling pathways, G-protein-coupled and phosphotyrosine-related, and an essential role of the G-protein-coupled signals for the lectin-induced respiratory burst in human monocytic THP-1 cells.

Authors:  T Matsuo; K Hazeki; O Hazeki; T Katada; M Ui
Journal:  Biochem J       Date:  1996-04-15       Impact factor: 3.857

8.  Granulocyte macrophage-colony stimulating factor stimulates both association and activation of phosphoinositide 3OH-kinase and src-related tyrosine kinase(s) in human myeloid derived cells.

Authors:  S Corey; A Eguinoa; K Puyana-Theall; J B Bolen; L Cantley; F Mollinedo; T R Jackson; P T Hawkins; L R Stephens
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

9.  Tyrosine phosphorylation of CD6 by stimulation of CD3: augmentation by the CD4 and CD2 coreceptors.

Authors:  S Wee; G L Schieven; J M Kirihara; T T Tsu; J A Ledbetter; A Aruffo
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.